The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Melanie S. Joy

Division of Nephrology and Hypertension

UNC Kidney Center

University of North Carolina School of Medicine

Chapel Hill

USA

[email]@med.unc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, USA. 2012
  • School of Medicine, University of North Carolina at Chapel Hill, UNC Kidney Center and Division of Nephrology and Hypertension, CB 7155, USA. 2010
  • School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, USA. 2002 - 2010
  • University of North Carolina Kidney Center, Chapel Hill, North Carolina 27599-7155, USA. 2009

References

  1. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Joy, M.S., La, M., Wang, J., Bridges, A.S., Hu, Y., Hogan, S.L., Frye, R.F., Blaisdell, J., Goldstein, J.A., Dooley, M.A., Brouwer, K.L., Falk, R.J. Br. J. Clin. Pharmacol (2012) [Pubmed]
  2. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. Joy, M.S., Frye, R.F., Stubbert, K., Brouwer, K.R., Falk, R.J., Kharasch, E.D. J. Clin. Pharmacol (2010) [Pubmed]
  3. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Joy, M.S., Boyette, T., Hu, Y., Wang, J., La, M., Hogan, S.L., Stewart, P.W., Falk, R.J., Dooley, M.A., Smith, P.C. Eur. J. Clin. Pharmacol. (2010) [Pubmed]
  4. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Joy, M.S., Dornbrook-Lavender, K., Blaisdell, J., Hilliard, T., Boyette, T., Hu, Y., Hogan, S.L., Candiani, C., Falk, R.J., Goldstein, J.A. Eur. J. Clin. Pharmacol. (2009) [Pubmed]
  5. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Joy, M.S., Hilliard, T., Hu, Y., Hogan, S.L., Dooley, M.A., Falk, R.J., Smith, P.C. Pharmacotherapy (2009) [Pubmed]
  6. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Joy, M.S., Dornbrook-Lavender, K.A., Chin, H., Hogan, S.L., Denu-Ciocca, C. Ann. Pharmacother (2008) [Pubmed]
  7. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Joy, M.S., Hogan, S.L., Thompson, B.D., Finn, W.F., Nickeleit, V. Nephrol. Dial. Transplant. (2007) [Pubmed]
  8. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Joy, M.S., Karagiannis, P.C., Peyerl, F.W. J. Manag. Care. Pharm (2007) [Pubmed]
  9. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Joy, M.S., Candiani, C., Vaillancourt, B.A., Chin, H., Hogan, S.L., Falk, R.J. Pharmacotherapy (2007) [Pubmed]
  10. Nephrology pharmacy: historical reflections and future challenges. Joy, M.S., Matzke, G.R. Ann. Pharmacother (2007) [Pubmed]
  11. Lanthanum carbonate. Joy, M.S., Kshirsagar, A., Candiani, C., Brooks, T., Hudson, J.Q. Ann. Pharmacother (2006) [Pubmed]
  12. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Joy, M.S., Nickeleit, V., Hogan, S.L., Thompson, B.D., Finn, W.F. Pharmacotherapy (2005) [Pubmed]
  13. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Joy, M.S., Kshirsagar, A.V., Franceschini, N. Ann. Pharmacother (2004) [Pubmed]
  14. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Joy, M.S., Finn, W.F. Am. J. Kidney Dis. (2003) [Pubmed]
  15. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Joy, M.S., Cefalu, W.T., Hogan, S.L., Nachman, P.H. Am. J. Kidney Dis. (2002) [Pubmed]
 
WikiGenes - Universities